Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -91.00% is 94% above its 2-year average of -1459.03%, near the high end of its 2-year range (-10218.33%–-5.18%).
103.66% below its 12-month average of -44.68%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.18%.
EBITDA MARGIN
-91.00%
EBITDA MARGIN AVG TTM
-44.68%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-103.66%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$529.90M
EBITDA Margin
-91.00%
TTM Avg
-44.68%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.09M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.43M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$535.61M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
Market Cap
$536.32M
EBITDA Margin
-17741.55%
TTM Avg
-126136.56%
3Y Avg
-126136.56%
5Y Avg
-126136.56%
Market Cap
$538.62M
EBITDA Margin
-4782.00%
TTM Avg
-3061.67%
3Y Avg
-6701.43%
5Y Avg
-4552.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $529.90M | -91.00% | -44.68% | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $534.45M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.09M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | 1.18% | -15.78% | -775.36% | -845.24% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | -970.11% | -861.99% | -583.02% | -735.09% |
| ProKidney Corp. (PROK)vs › | $536.32M | -17741.55% | -126136.56% | -126136.56% | -126136.56% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $536.98M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $538.62M | -4782.00% | -3061.67% | -6701.43% | -4552.91% |
| Immix Biopharma, Inc. (IMMX)vs › | $520.08M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
Gross Margin
82.9%
EBITDA Margin
-91.0%
Operating Margin
-91.4%
Net Margin
-41.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5.18% |
| 2026-03-31 | -26.36% |
| 2025-12-31 | -10.07% |
| 2025-09-30 | -30.53% |
| 2025-06-30 | -151.26% |
| 2025-03-31 | -275.91% |
| 2024-12-31 | -199.65% |
| 2024-09-30 | -431.78% |
| 2024-06-30 | -1052.74% |
| 2024-03-31 | -3647.49% |
| 2023-12-31 | -10218.33% |
